ClinicalTrials.gov
ClinicalTrials.gov Menu

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01833039
Recruitment Status : Completed
First Posted : April 16, 2013
Last Update Posted : February 5, 2018
Sponsor:
Collaborator:
Pharmacyclics LLC.
Information provided by (Responsible Party):
Janssen Biotech, Inc.

Brief Summary:
The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.

Condition or disease Intervention/treatment Phase
Relapsed or Refractory Mantle Cell Lymphoma Drug: Ibrutinib Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 163 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Actual Study Start Date : May 15, 2013
Actual Primary Completion Date : August 28, 2017
Actual Study Completion Date : August 28, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
Drug Information available for: Ibrutinib
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Ibrutinib
Ibrutinib
Drug: Ibrutinib
Ibrutinib



Primary Outcome Measures :
  1. Percentage of Patients With Treatment Emergent Adverse Experiences during the study. [ Time Frame: Start of study drug to 30 Days post study drug administration ]
    Percentage of Patients With Treatment Emergent Adverse Experiences during the study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients, 18 years of age and older, with Mantle Cell Lymphoma who have relapsed or refractory disease after prior therapy are eligible.

Exclusion Criteria:

  • Patients eligible for enrollment in any other ongoing clinical study of ibrutinib are not eligible.
  • Patients previously treated with ibrutinib are not eligible.
  • Patients enrolled in another interventional clinical study with therapeutic intent are not eligible.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01833039


  Show 52 Study Locations
Sponsors and Collaborators
Janssen Biotech, Inc.
Pharmacyclics LLC.

Responsible Party: Janssen Biotech, Inc.
ClinicalTrials.gov Identifier: NCT01833039     History of Changes
Other Study ID Numbers: CR101862
PCI-32765MCL4001 ( Other Identifier: Janssen )
First Posted: April 16, 2013    Key Record Dates
Last Update Posted: February 5, 2018
Last Verified: January 2018

Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Janssen Biotech, Inc.:
Mantle Cell Lymphoma
Ibrutinib

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Mantle-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin